India markets closed
  • BSE SENSEX

    48,732.55
    +41.75 (+0.09%)
     
  • Nifty 50

    14,677.80
    -18.70 (-0.13%)
     
  • USD/INR

    73.2310
    -0.2290 (-0.31%)
     
  • Dow

    34,382.13
    +360.68 (+1.06%)
     
  • Nasdaq

    13,429.98
    +304.99 (+2.32%)
     
  • BTC-INR

    3,516,035.25
    -86,429.50 (-2.40%)
     
  • CMC Crypto 200

    1,398.33
    +39.77 (+2.93%)
     
  • Hang Seng

    28,027.57
    +308.90 (+1.11%)
     
  • Nikkei

    28,084.47
    +636.46 (+2.32%)
     
  • EUR/INR

    88.9900
    +0.2390 (+0.27%)
     
  • GBP/INR

    103.2952
    +0.0881 (+0.09%)
     
  • AED/INR

    19.8930
    -0.0630 (-0.32%)
     
  • INR/JPY

    1.4903
    +0.0032 (+0.22%)
     
  • SGD/INR

    54.9660
    -0.1400 (-0.25%)
     

Antibe Therapeutics to Present at 2021 Bloom Burton & Co. Healthcare Investor Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
  • Oops!
    Something went wrong.
    Please try again later.

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for inflammation arising from a wide range of medical conditions, is pleased to announce its participation in the Bloom Burton & Co. Healthcare Investor Conference being held virtually on Tuesday, April 20 and Wednesday, April 21. Dan Legault, Antibe’s CEO, will deliver the Company’s presentation and will discuss recent business highlights and its growth strategy:

Date: Wednesday, April 21, 2021
Time: 11:00 am (Eastern Time)

A link to the webcast of the presentation will be available on the News and Events section of the Company’s website at antibethera.com. Following the presentation, a replay of the webcast will be available for 90 days.

The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from Canada’s premier publicly traded and private companies through presentations and private meetings.

About Antibe Therapeutics Inc.

Antibe is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions. The Company’s current pipeline includes three assets that seek to overcome the gastrointestinal ("GI") ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs ("NSAIDs"). Antibe’s lead drug, otenaproxesul, is preparing to enter Phase III for the treatment of osteoarthritis pain. Additional assets under development include a safer alternative to opioids for peri-operative pain, and a GI-protective alternative to low-dose aspirin. The Company’s next target is inflammatory bowel disease ("IBD"), a condition long in need of safer, more effective therapies. Learn more at antibethera.com.

About Bloom Burton & Co.

Bloom Burton & Co. (Bloom Burton Securities Inc.) is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies. Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets professionals who perform a deep level of diligence, which combined with a creative and entrepreneurial approach, assists clients in achieving the right monetization events. Bloom Burton and its affiliates provide capital raising, M&A advisory, equity research, business strategy and scientific consulting, advisory on direct investing and company creation and incubation services. Bloom Burton Securities Inc. is a member of the Investment Industry Regulatory Organization of Canada (IIROC) and is also a member of the Canadian Investor Protection Fund (CIPF).

View source version on businesswire.com: https://www.businesswire.com/news/home/20210414005233/en/

Contacts

Antibe Therapeutics Inc.
Christina Cameron
VP Investor Relations
+1 416-577-1443
christina@antibethera.com